Stelis Biopharma Builds Facility in Malaysia
The multi-product biopharmaceutical manufacturing facility is scheduled to start up in 2017.
Stelis Biopharma began construction of its customized, multi-product biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia, the company announced in a Dec. 3, 2014 press release. Stelis Biopharma is a wholly owned subsidiary of Strides Arcolab.
The construction and fit-out of the facility is expected to be completed in 24 months, and commercial operations are targeted to begin mid-2017. The 140,000-ft2 facility will incorporate single-use bio-processing technology with both mammalian and microbial manufacturing suites. When complete, it will be one of the few regulated-market approvable facilities in the region with end-to-end capability including sterile fill-finish across all formats. The facility will also house an R&D unit to conduct scale-up and process development studies. At peak operations, the facility will employ 180 people.
Source: Strides Arcolab
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
